抄録
Prospective studies were carried out in the patients with acquired aplastic anemia to evoluate the hematopoietic effects of androstanes. The androstanes used were oxymetholone, methenolone, and fluoxymesterone. In three months, the remission rate was shown in 29∼44% for of the patients, but rises to 45∼60% of the patients in six months, there was no significant difference among the regimens used in remission rate.
It was presumed that some cases of aplastic anemia respond well to androstanes while others fail to do so. Both following the initiation of adminstration, about 70% of the patients showed abnormal S-GOT, S-GPT. Signs of virilization were observed in about 25∼30% at three months of therapy and in about 35∼50% at six months. This prospective studies indicate that these androstanes may be considered as valuable drugs in the therapy of aplastic anemia.
